The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
Hepatocellular Carcinoma
PROCEDURE: TAI
OS, overall survival, From date of randomization until the date of death from any cause, assessed up to 60 months
RFS, recurrence-free survival, From date of randomization until the date of recurrence, assessed up to 60 months|recurrence rate, recurrence rate, 1 year, 2 year, 3 year, 5 year after surgery|PFS, progression free survival, From date of randomization until the date of progression, assessed up to 60 months
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.